期刊文献+

索拉菲尼诱导的肝癌耐药细胞株的建立及其生物学特性 被引量:3

Establishment and biological characteristics of sorafenib-resistant hepatocellular carcinoma cell lines
下载PDF
导出
摘要 目的建立索拉菲尼诱导的PLC/PRF/5和Huh7耐药细胞株,并研究其耐药细胞的生物学特性。方法通过药物敏感性实验CCK8法测定索拉菲尼的半数抑制浓度IC50值;采用体外间歇诱导法,使用PLC/PRF/5和Huh7各自IC50值作为筛选浓度,建立索拉菲尼诱导的耐药细胞株模型;Real time-PCR检测5种耐药基因(GST-π、LRP、MDR1、MRP、TopoⅡ)在耐药组和对照组中的表达差异;Western blot检测MAPK信号通路中关键信号因子细胞外调节蛋白激酶(extra-cellular regulated protein kinases,ERK)ERK1/2在不同组别细胞中的磷酸化水平差异。结果所筛选的PLC/PRF/5和Huh7耐药组细胞与对照组细胞相比较,其细胞生存率有显著性提高(P<0.05);5种耐药基因中MDR1的表达有显著性上调(P<0.05);索拉菲尼作用靶点的下游信号因子ERK1/2的磷酸化水平上调。结论成功地在体外建立索拉菲尼诱导的PLC/PRF/5和Huh7耐药细胞株,其耐药机制可能与ERK1/2的磷酸化水平上调导致耐药基因MDR1高表达有关。 Objective To establish sorafenib-indeuced drug resistant hepatoma cell lines and investi- gate their biological characteristics. Methods CCK8 assay was used for drug sensitivity of hepatocellular car- cinoma cell lines PLC/PRF/5 and Huh7 to sorafenib. By using intermittent induction in vitro and the obtained IC50 value as a screening concentration, we screened and established drug resistant cell lines. Expression of drug resistant genes, GST-IT, LRP, MDR1, MRP and Topo I] , were examined by real time-PCR. Western blot analysis was applied to examine the phosphorylation level of extracellular regulated protein kinases 1/2 (ERK1/2). Results Sorafenib-resistant PLC/PRF/5 and Huh7 cells had a longer survival rate compared with corresponding control cells (P 〈 0. 05 ). MDR1 was the only one from the 5 resistance genes who had sig- nificantly increased expression (P 〈 0.05 ). Furthermore, sorafenib was found to induce the phosphorylation of ERK1/2. Conclusion Sorafenib resistant hepatoma cell lines PLC/PRF/5 and Huh7 are successfully estab- lished. The underlying mechanism may be associated with sorafenib-induced ERK1/2 activation that leads to high expression of drug resistant gene MDRI.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第14期1366-1369,共4页 Journal of Third Military Medical University
基金 国家重点基础研究发展计划(973计划,2004CB518804)~~
关键词 索拉菲尼 肿瘤 抗药性 肝细胞癌 sorafenib drug resistance, neoplasm carcinoma, hepatocellular
  • 相关文献

参考文献4

二级参考文献27

  • 1Edgar Staren,Takeshi Iwamura,Hubert Appert,John Howard.Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2[J].World Journal of Gastroenterology,2001,7(1):143-148. 被引量:12
  • 2王其,陈孝平,张万广,张必翔.人肝癌HepG2多药耐药细胞系的部分生物学性状研究[J].中华实验外科杂志,2004,21(5):538-540. 被引量:40
  • 3Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304(5676) : 1497 - 1500.
  • 4Yamaguchi M, Matsumoto T, Tate G,'et al. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene [ J ]. J Gastroenterol, 2004, 39(9): 904-905.
  • 5Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EG- FR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer [J]. Lancet Oncol, 2008, 9(10): 962-972.
  • 6Konner J, Schilder R J, DeRosa F A, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer[ J]. Gynecol Oncol, 2008, 110(2) : 140 -145.
  • 7Robert F, Blumenschein G, Herbst R S, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer[ J]. J Clin Oncol, 2005, 23 (36) : 9089 - 9096.
  • 8Fukuoka M, Yano S, Giaccone G, etal. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nun-small-cell lung cancer ( The IDEAL 1 Trial) [ J ]. J Clin Oncol, 2003, 21 (12) : 2237-2246.
  • 9Nimeiri H S, Oza A M, Morgan R J, etal. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia[ J]. Gynecol Oncol, 2008, 110(1 ) : 49 - 55.
  • 10Zhu X, Wu S, Dahut W L, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis[ J ]. Am J Kidney Dis, 2007, 49(2) : 186 -193.

共引文献55

同被引文献36

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部